Real life outcomes of the AT-Torbi 709MP aspheric toric IOL in a publicly funded Irish hospital

Session Details

Session Title: Pseudophakic IOLs: Toric II

Session Date/Time: Sunday 11/09/2016 | 16:00-18:00

Paper Time: 17:02

Venue: Auditorium C6

First Author: : E.Duignan IRELAND

Co Author(s): :    P. Mullaney                    

Abstract Details

Purpose:

To evaluate the visual and refractive outcomes of the AT Torbi 709MP (Carl Zeiss) aspheric toric intraocular lens in a real-life setting.

Setting:

A publicly funded regional university-affiliated hospital in Ireland

Methods:

In this prospective interventional case series, consecutive patients with corneal astigmatism of at least 1.5D (dioptres), and no contraindication to toric IOL surgery, underwent implantation of an AT Torbi 709MP toric IOL. Toric IOL calculation was carried out using online Z Calc software (Carl Zeiss). Follow-up appointments were carried out by community optometrists who evaluated UDVA (uncorrected distance visual acuity), BCVA (best-corrected visual acuity) and subjective refraction at one month.

Results:

We evaluated 69 eyes of 66 patients. There were 35 females and 31 males with a mean age of 76 (SD ±11, range 45-95). Average pre-operative corneal astigmatism was 2.65D (SD ±1D, range 1.6-6.26D). Preoperative BCVA ranged from 0.1 to 2.4 (mean 0.6). Mean postoperative absolute value of refractive cylinder was ±1.23D (SD ±0.93D, range 0-4.5D) with 19% and 58% achieving a level of 0.5D or less and 1.0D or less, respectively. The percentage of patients with a spherical equivalent within 0.5D of emmetropia was 56% and within 1.0D was 85%. Post-operative UDVA ranged from 0.1 to 2.10 (mean 0.4). Post-operative BCVA ranged from -0.1 to 2.10 (mean 0.2).

Conclusions:

Toric IOLs are an effective measure in the real-life setting to reduce astigmatism and increase UDVA. Community optometrist assessment at one month is sufficient to address refractive error but not rotational stability. Further investigation of spectacle use and patient satisfaction in this cohort is warranted.

Financial Disclosure:

NONE